新英格兰医学期刊:医治窦汇区淋巴瘤的新计划方案

  • A+
所属分类:医疗资讯

新英格兰医学期刊:医治窦汇区淋巴瘤的新计划方案 。
印度的natco马法兰盘Melphalan摘 要:。新英格兰医学期刊:医治窦汇区淋巴瘤的新计划方案骨髓瘤是恶变浆细胞病中最普遍的一种类型。出现异常浆细胞可以占用或抑止脊髓中别的它体细胞的生长发育。这类抑制型很有可能会造成 缺铁性贫血、内出血及其抗感染药工作能力减低。窦汇区骨髓瘤是一种不常用的癌症。在国外,每一年大概30000人将被诊治判断为窦汇区骨髓瘤。2012年,全球约114250人被诊断为窦汇区骨髓瘤,现阶段我国尚欠缺这行的精确数据信息。达雷木替尼(Daratumumab)是第一个被准许用来医治窦汇区淋巴瘤的单抗,靶向治疗CD38的IgG1κ,可使反复发/不易治窦汇区骨髓瘤病患者造成更加深入更长久的回应,而且安全性性能也可接纳。在2016年6月5日纽约的ASCO交流会上,Antonio Palumbo博士研究生产生了有关达雷木替尼(Daratumumab)协同硼替佐米 阿昔洛韦医治反复发/不易治窦汇区淋巴瘤的关键科学研究,这一新医治对策看起来能快速操纵癌症生长发育。但针对初治的窦汇区骨髓瘤一样合理吗?可以看《新英格兰医科学杂志》刚(2022年2月8日线上先给)公布的分析結果。《壹篇》按《新英格兰医科学杂志》2022年2月8日线上先给http://www.nejm.org/doi/full/10.1056/NEJMoa1714678?query=featured_home

达雷木替尼 硼替佐米、美法仑、泼尼松片医治初治骨髓瘤

环境针对新诊治判断出的、不宜开展自体干细胞移殖的窦汇区骨髓瘤病患者,硼替佐米、美法仑和泼尼松片协同诊治是一种规范治疗方法。在不易治或重反复性窦汇区骨髓瘤病患者中,达雷木替尼协同规范治疗方法表明出有治疗效果。方式在此项3期临床试验中,大家将706名新诊治判断出的、不宜开展自体干细胞移殖的窦汇区骨髓瘤病患者随机分组,一组接纳9个期限的单纯性硼替佐米、美法仑和泼尼松片医治(对照实验),一组接纳硼替佐米、美法仑和泼尼松片协同达雷木替尼医治(达雷木替尼组),直到恶性肿瘤进度。关键终端为无进度存活。結果在一项事前确认的前中期剖析中,负相关随诊16.5个月,达雷木替尼组18个月的无进度存活概率为71.6%(95%可信区间[CI],65.5-76.8)、对照实验50.2%(95%CI,43.2-56.7)(恶性肿瘤进度或过世的危险性比,0.50;95%CI,0.38-0.65;P<0.001)。达雷木替尼组总减轻率是90.9%,而对照实验为73.9%(P<0.001);放任不管或更好减轻(包含标准化的放任不管)率是42.6%较为24.4%(P<0.001)。在达雷木替尼组,22.3%病患者的细微残余疾病(定义数值每10的5三次方个白细胞计数中一个肿瘤干细胞)为呈阴性,而在对照实验,6.2%的病患者为呈阴性(P<0.001)。最普遍的3、四级副作用为血液系统:单核细胞降低(达雷木替尼组39.9%的病患者发生、对照实验38.7%的病患者发生)、血小板减少症(各自为34.4%、37.6%)、缺铁性贫血(各自为15.9%、19.8%)。达雷木替尼组3、四级患病率为23.1%、对照实验14.7%,因为细菌感染而医治终断率各自为0.9%、1.4%。有27.7%的病患者发生了滴注达雷木替尼有关的反映。结果在新诊治判断出的、不宜开展自体干细胞移殖的窦汇区骨髓瘤病患者中,达雷木替尼协同硼替佐米、美法仑、泼尼松片与一样治疗方法但没有达雷木替尼对比,促使恶性肿瘤进度或过世的风险更低。含达雷木替尼治疗方法与越来越多的3、四级感柒有关。《壹篇》南南和晨晨

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

BackgroundThe combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refractory multiple myeloma.MethodsIn this phase新英格兰医学期刊:医治窦汇区淋巴瘤的新计划方案 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone (control group) or with daratumumab (daratumumab group) until disease progression. The primary end point was progression-free survival.ResultsAt a median follow-up of 16.5 months in a prespecified interim analysis, the 18-month progression-free survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in the daratumumab group and 50.2% (95% CI, 43.2 to 56.7) in the control group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.38 to 0.65; P<0.001). The overall response rate was 90.9% in the daratumumab group, as compared with 73.9% in the control group (P<0.001), and the rate of complete response or better (including stringent complete response) was 42.6%, versus 24.4% (P<0.001). In the daratumumab group, 22.3% of the patients were negative for minimal residual disease (at a threshold of 1 tumor cell per 105 white cells), as compared with 6.2% of those in the control group (P<0.001). The most common adverse events of grade 3 or 4 were hematologic: neutropenia (in 39.9% of the patients in the daratumumab group and in 38.7% of those in the control group), thrombocytopenia (in 34.4% and 37.6%, respectively), and anemia (in 15.9% and 19.8%, respectively). The rate of grade 3 or 4 infections was 23.1% in the daratumumab group and 14.7% in the control group; the rate of treatment discontinuation due to infections was 0.9% and 1.4%, respectively. Daratumumab-associated infusion-related r新英格兰医学期刊:医治窦汇区淋巴瘤的新计划方案eactions occurred in 27.7% of the patients.ConclusionsAmong patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without daratumumab. The daratumumab-containing regimen was associated with more grade 3 or 4 infections. (Funded by Janssen Research and Development; ALCYONE ClinicalTrials.gov number, NCT02195479.)《壹篇》(与桓兴医讯同歩)系关键朝向医护人员的服务性【微信号码:yaodaoyaofang】,不因盈利为目地,不开展一切有偿服务资询和服务项目,不销售一切商品,与ASCO、CSCO等全部技术专业学好和组织并没有任何的关联和联络,都不意味着一切官方网学好发音。文章照片均来源于互联网,不做商业行为,若有著作权异议请与《壹篇》联络。不断关注点赞——【手机微信:india2080】、称赞和分享——【手机微信:india2080】是一种心态和适用。
马法兰盘(ALPHALAN)Alphalan Melphalan Tablets 2mg 馬法蘭片 马法兰 药道全世界,助推性命。印度的全世界海淘药店:。

  • 微信咨询
  • 这是我的微信扫一扫
  • weinxin
  • WhatsApp 沟通
  • 手机扫一扫二维码
  • weinxin

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: